Novartis announces change to the Executive Committee

  • Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021

  • Thomas Kendris appointed Chief Legal Officer ad interim

Basel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021.

Thomas N. Kendris, currently Global Head Litigation and US Country President …

/by

Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate

  • Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.
  • Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. Delivery from manufacturing site in Kundl, Austria expected to start in summer 2021.
  • One of several agreements Novartis is reviewing on a global basis to help …
/by

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

  • Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flow
  • Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as well as all other members who stood for re-election
  • Shareholders approve all other proposals of the Board of Directors, including the 2020 Compensation Report in an advisory vote, as well as the future Board and Executive …
/by

Take a visual tour of medicines that target RNA

Cells have a built-in search and delete function. The existence of such a system came as a surprise 30 years ago, when researchers experimenting with petunias discovered it accidentally.

Today, however, scientists are wielding that capability as powerful medicine.

Medicines that leverage this search and delete system are designed to block the production of disease-related proteins by targeting RNA, the instructions normally used by cells to build proteins. This new type of therapeutic has the potential to interrupt almost any disease process in the body. Novartis is developing …

/by

On a mission to transform planetary health

Illustration of planet earth

“Planetary health is directly related to human health and if we don’t change, the human species will disappear.” This was the stark warning delivered by Patrice Matchaba, Head, US Corporate Responsibility and President, Novartis US Foundation, at the inaugural One Young World (OYW)- …

/by

Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing

  • Adds tislelizumab, a uniquely designed anti-PD-1 monoclonal antibody for monotherapy and proprietary combination cancer therapies with Novartis portfolio and pipeline therapies
  • Novartis will co-develop tislelizumab with BeiGene and expand access to patients in North America, Europe and Japan
  • Specifically designed to minimize binding to FcγR on macrophages, tislelizumab will be key asset in Novartis immuno-oncology combination strategy

Basel, February 26, 2021 …

/by

Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis

  • Cosentyx® (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial1,2,3.
  • Up to two-thirds of patients with PsA suffer from axial manifestations4
  • Phase IIIb MAXIMISE trial showed treatment with Cosentyx improved the signs and symptoms of axial manifestations of PsA as early as …
/by

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation 
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa …
/by

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

  • Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3 
  • Expanded indication enables potential treatment of more adults with left ventricular ejection fraction (LVEF) below normal, the group where benefits are most clearly evident1 
  • Of the more than 6 million Americans …
/by

Novartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen

  • Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84% vs 16%)1 
  • Sensoready autoinjector pen ranked highest for “easy to perform self-injection with the pen,” “patient able to use independently” and “ease of preparation and set-up” by both patients and nurses1 
  • Kesimpta is a targeted B-cell therapy that delivers superior efficacy and post hoc analysis showed that …
/by